Big Pharma Advances Efforts In TB But Pricing Stays Key Concern
Price cuts, new treatments for TB and alliances to improve access to these medicines were among the key talking points at the recently concluded Union World Conference on Lung Health in India. TB survivors and activists were also vocal and pressed hard for their demands to be heard.
You may also be interested in...
Tuberculosis drug pretomanid gets endorsement, with Phase III trial waiver, from a key expert panel that advises India's drugs regulator, but roll out plan needs to be defined under the country’s national TB program, say health activists.
J&J ties up with agencies, Indian government to build capacity and widen access to Sirturo for TB patients.
Johnson & Johnson maintains its game-changing antibiotic bedaquiline for drug-resistant tuberculosis is priced "fairly" at $400 for a six-month course, and terms calls by public health advocates to cut the cost to $1 a day “not realistic.”